Interestingly, inhibition of AKR1C3 has overcome tumor resistance also towards idarubicin (Hofman et al. 2014), which is possibly caused by modulation of resistance mechanism mediated by AKR1C3, which are not associated with the metabolism of anthracyclines. Here, AKR1C3 is linked to neoplasm.